{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.1","value":"20.4"},{"groupId":"OG001","spread":"10.3","value":"18.3"},{"groupId":"OG002","spread":"11.1","value":"22.5"},{"groupId":"OG003","spread":"24.6","value":"23.7"},{"groupId":"OG004","spread":"9.51","value":"17.8"},{"groupId":"OG005","spread":"14.1","value":"22.4"},{"groupId":"OG006","spread":"14.5","value":"28.8"},{"groupId":"OG007","spread":"13.4","value":"22.3"},{"groupId":"OG008","spread":"26.7","value":"21.7"},{"groupId":"OG009","spread":"14.4","value":"26.9"},{"groupId":"OG010","spread":"11.6","value":"25.1"},{"groupId":"OG011","spread":"12.0","value":"21.3"},{"groupId":"OG012","spread":"14.1","value":"23.1"},{"groupId":"OG013","spread":"12.4","value":"18.1"},{"groupId":"OG014","spread":"10.1","value":"20.1"},{"groupId":"OG015","spread":"11.1","value":"22.3"},{"groupId":"OG016","spread":"10.7","value":"17.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"124"},{"groupId":"OG002","value":"129"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"45"},{"groupId":"OG008","value":"48"},{"groupId":"OG009","value":"57"},{"groupId":"OG010","value":"16"},{"groupId":"OG011","value":"43"},{"groupId":"OG012","value":"118"},{"groupId":"OG013","value":"21"},{"groupId":"OG014","value":"117"},{"groupId":"OG015","value":"87"},{"groupId":"OG016","value":"82"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.4","value":"23.5"},{"groupId":"OG001","spread":"15.1","value":"23.5"},{"groupId":"OG002","spread":"15.2","value":"25.6"},{"groupId":"OG003","spread":"17.0","value":"26.5"},{"groupId":"OG004","spread":"13.6","value":"17.3"},{"groupId":"OG005","spread":"20.1","value":"25.5"},{"groupId":"OG006","spread":"15.9","value":"31.6"},{"groupId":"OG007","spread":"17.3","value":"23.8"},{"groupId":"OG008","spread":"12.4","value":"20.7"},{"groupId":"OG009","spread":"22.3","value":"35.7"},{"groupId":"OG010","spread":"16.6","value":"27.4"},{"groupId":"OG011","spread":"16.9","value":"26.2"},{"groupId":"OG012","spread":"18.3","value":"27.7"},{"groupId":"OG013","spread":"16.0","value":"18.6"},{"groupId":"OG014","spread":"23.9","value":"27.0"},{"groupId":"OG015","spread":"16.2","value":"23.9"},{"groupId":"OG016","spread":"13.0","value":"21.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"117"},{"groupId":"OG003","value":"142"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"41"},{"groupId":"OG008","value":"45"},{"groupId":"OG009","value":"50"},{"groupId":"OG010","value":"15"},{"groupId":"OG011","value":"38"},{"groupId":"OG012","value":"109"},{"groupId":"OG013","value":"20"},{"groupId":"OG014","value":"104"},{"groupId":"OG015","value":"85"},{"groupId":"OG016","value":"74"}],"units":"Participants"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.6","value":"24.6"},{"groupId":"OG001","spread":"15.9","value":"23.8"},{"groupId":"OG002","spread":"18.2","value":"28.3"},{"groupId":"OG003","spread":"17.8","value":"29.7"},{"groupId":"OG004","spread":"14.3","value":"20.6"},{"groupId":"OG005","spread":"24.2","value":"23.2"},{"groupId":"OG006","spread":"16.3","value":"32.3"},{"groupId":"OG007","spread":"22.9","value":"29.3"},{"groupId":"OG008","spread":"18.9","value":"23.6"},{"groupId":"OG009","spread":"22.6","value":"35.7"},{"groupId":"OG010","spread":"19.7","value":"29.4"},{"groupId":"OG011","spread":"18.9","value":"28.1"},{"groupId":"OG012","spread":"20.9","value":"28.4"},{"groupId":"OG013","spread":"21.5","value":"19.8"},{"groupId":"OG014","spread":"17.6","value":"29.0"},{"groupId":"OG015","spread":"18.1","value":"27.7"},{"groupId":"OG016","spread":"17.7","value":"25.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"94"},{"groupId":"OG003","value":"96"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"34"},{"groupId":"OG008","value":"37"},{"groupId":"OG009","value":"51"},{"groupId":"OG010","value":"17"},{"groupId":"OG011","value":"33"},{"groupId":"OG012","value":"93"},{"groupId":"OG013","value":"14"},{"groupId":"OG014","value":"80"},{"groupId":"OG015","value":"62"},{"groupId":"OG016","value":"60"}],"units":"Participants"}],"title":"Day 43"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.3","value":"26.2"},{"groupId":"OG001","spread":"16.1","value":"23.4"},{"groupId":"OG002","spread":"14.1","value":"26.5"},{"groupId":"OG003","spread":"14.5","value":"28.9"},{"groupId":"OG004","spread":"19.8","value":"22.2"},{"groupId":"OG007","spread":"22.4","value":"29.9"},{"groupId":"OG008","spread":"11.7","value":"18.2"},{"groupId":"OG009","spread":"25.5","value":"39.8"},{"groupId":"OG010","spread":"18.7","value":"25.5"},{"groupId":"OG011","spread":"22.8","value":"29.7"},{"groupId":"OG012","spread":"21.5","value":"27.3"},{"groupId":"OG013","spread":"15.2","value":"16.2"},{"groupId":"OG014","spread":"18.1","value":"30.6"},{"groupId":"OG015","spread":"20.3","value":"28.5"},{"groupId":"OG016","spread":"15.6","value":"24.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"86"},{"groupId":"OG003","value":"78"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"26"},{"groupId":"OG008","value":"36"},{"groupId":"OG009","value":"46"},{"groupId":"OG010","value":"15"},{"groupId":"OG011","value":"30"},{"groupId":"OG012","value":"80"},{"groupId":"OG013","value":"11"},{"groupId":"OG014","value":"55"},{"groupId":"OG015","value":"48"},{"groupId":"OG016","value":"57"}],"units":"Participants"}],"title":"Day 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.5","value":"27.9"},{"groupId":"OG001","spread":"40.1","value":"31.0"},{"groupId":"OG002","spread":"16.6","value":"28.1"},{"groupId":"OG003","spread":"15.4","value":"29.9"},{"groupId":"OG004","spread":"15.5","value":"22.0"},{"groupId":"OG007","spread":"23.6","value":"28.8"},{"groupId":"OG008","spread":"14.2","value":"21.0"},{"groupId":"OG009","spread":"33.4","value":"38.4"},{"groupId":"OG010","spread":"17.6","value":"27.8"},{"groupId":"OG011","spread":"22.1","value":"29.4"},{"groupId":"OG012","spread":"31.8","value":"33.4"},{"groupId":"OG013","spread":"15.3","value":"19.6"},{"groupId":"OG014","spread":"18.8","value":"31.1"},{"groupId":"OG015","spread":"23.0","value":"30.4"},{"groupId":"OG016","spread":"14.7","value":"24.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"83"},{"groupId":"OG003","value":"70"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"27"},{"groupId":"OG008","value":"33"},{"groupId":"OG009","value":"46"},{"groupId":"OG010","value":"13"},{"groupId":"OG011","value":"24"},{"groupId":"OG012","value":"74"},{"groupId":"OG013","value":"8"},{"groupId":"OG014","value":"48"},{"groupId":"OG015","value":"36"},{"groupId":"OG016","value":"47"}],"units":"Participants"}],"title":"Day 71"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.9","value":"27.8"},{"groupId":"OG001","spread":"16.7","value":"27.7"},{"groupId":"OG002","spread":"18.1","value":"29.7"},{"groupId":"OG003","spread":"16.8","value":"28.9"},{"groupId":"OG004","spread":"29.0","value":"24.9"},{"groupId":"OG005","spread":"0.988","value":"8.03"},{"groupId":"OG006","spread":"18.3","value":"37.9"},{"groupId":"OG007","spread":"23.7","value":"35.6"},{"groupId":"OG008","spread":"15.8","value":"23.7"},{"groupId":"OG009","spread":"27.2","value":"39.7"},{"groupId":"OG010","spread":"20.2","value":"34.4"},{"groupId":"OG011","spread":"20.5","value":"34.7"},{"groupId":"OG012","spread":"28.3","value":"39.1"},{"groupId":"OG013","spread":"3.60","value":"19.3"},{"groupId":"OG014","spread":"20.7","value":"35.6"},{"groupId":"OG015","spread":"22.0","value":"31.2"},{"groupId":"OG016","spread":"14.6","value":"28.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"67"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"22"},{"groupId":"OG008","value":"24"},{"groupId":"OG009","value":"43"},{"groupId":"OG010","value":"11"},{"groupId":"OG011","value":"23"},{"groupId":"OG012","value":"47"},{"groupId":"OG013","value":"2"},{"groupId":"OG014","value":"31"},{"groupId":"OG015","value":"24"},{"groupId":"OG016","value":"41"}],"units":"Participants"}],"title":"Day 85"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"13.6","value":"28.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"}],"units":"Participants"}],"title":"Day 99"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.0","value":"36.9"},{"groupId":"OG002","spread":"40.2","value":"39.1"},{"groupId":"OG003","spread":"24.0","value":"33.1"},{"groupId":"OG004","spread":"22.1","value":"28.8"},{"groupId":"OG005","value":"34.2"},{"groupId":"OG006","spread":"12.7","value":"44.2"},{"groupId":"OG007","spread":"76.7","value":"58.6"},{"groupId":"OG008","spread":"11.3","value":"25.9"},{"groupId":"OG011","spread":"18.2","value":"35.7"},{"groupId":"OG012","spread":"25.1","value":"40.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"13"},{"groupId":"OG008","value":"13"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"13"},{"groupId":"OG012","value":"31"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"}],"units":"Participants"}],"title":"Day 127"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.8","value":"36.6"},{"groupId":"OG001","spread":"19.8","value":"39.1"},{"groupId":"OG002","spread":"18.2","value":"31.4"},{"groupId":"OG003","spread":"14.0","value":"31.9"},{"groupId":"OG004","spread":"28.1","value":"24.7"},{"groupId":"OG005","value":"10.5"},{"groupId":"OG007","spread":"20.2","value":"35.3"},{"groupId":"OG008","spread":"11.4","value":"28.7"},{"groupId":"OG009","spread":"26.8","value":"47.1"},{"groupId":"OG010","value":"43.6"},{"groupId":"OG011","spread":"19.2","value":"38.8"},{"groupId":"OG012","spread":"27.3","value":"49.3"},{"groupId":"OG014","spread":"14.7","value":"32.5"},{"groupId":"OG015","spread":"20.0","value":"28.3"},{"groupId":"OG016","spread":"31.6","value":"37.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"13"},{"groupId":"OG009","value":"34"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"13"},{"groupId":"OG012","value":"22"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"6"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"7"}],"units":"Participants"}],"title":"Day 169"}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"124"},{"groupId":"OG002","value":"129"},{"groupId":"OG003","value":"154"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"45"},{"groupId":"OG008","value":"48"},{"groupId":"OG009","value":"57"},{"groupId":"OG010","value":"17"},{"groupId":"OG011","value":"43"},{"groupId":"OG012","value":"118"},{"groupId":"OG013","value":"21"},{"groupId":"OG014","value":"117"},{"groupId":"OG015","value":"87"},{"groupId":"OG016","value":"82"}],"units":"Participants"}],"description":"Serum Ctrough concentration of Avelumab is reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG000","title":"Primary Expansion Cohort: NSCLC, Post-platinum Doublet"},{"description":"Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG001","title":"Primary Expansion Cohort: NSCLC, First Line"},{"description":"Participants with gastric and gastroesophageal cancer who progressed/non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG002","title":"Primary Expansion Cohort: GC/GEJC (Progressed/Non Progressed)"},{"description":"Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG003","title":"Primary Expansion Cohort: Metastatic Breast Cancer"},{"description":"Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG004","title":"Secondary Expansion Cohort: Adrenocortical Carcinoma"},{"description":"Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG005","title":"Secondary Expansion Cohort: Colorectal Cancer"},{"description":"Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG006","title":"Secondary Expansion Cohort: Castrate-resistant Prostate Cancer"},{"description":"Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG007","title":"Secondary Expansion Cohort: Melanoma"},{"description":"Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG008","title":"Secondary Expansion Cohort: Mesothelioma"},{"description":"Participants with Renal cell carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a first-line therapy in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG009","title":"Secondary Expansion Cohort: Renal Cell Carcinoma (First Line)"},{"description":"Participants with Renal cell carcinoma who failed 1 prior systemic first-line regimen received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a second line treatment in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG010","title":"Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)"},{"description":"Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG011","title":"Secondary Expansion Cohort: Urothelial Carcinoma"},{"description":"Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG012","title":"Secondary Expansion Cohort: Ovarian Cancer"},{"description":"Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG013","title":"Efficacy Expansion Cohort: GC/GEJC, Third Line"},{"description":"Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG014","title":"Efficacy Expansion Cohort: HNSCC"},{"description":"Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG015","title":"Efficacy Expansion Cohort: Ovarian Cancer"},{"description":"Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.","id":"OG016","title":"Efficacy Expansion Cohort: Urothelial Carcinoma"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic analysis set was used. Here \"Overall number of participants analyzed\" signifies those who were evaluable for this outcome measure and \"Number analyzed\" signifies those who were evaluable at specified time points. Data for \"primary expansion cohort: GC/GEJC Progressed\" and \"primary expansion cohort: GC/GEJC Non progressed\" arms was reported as a single arm \"primary expansion cohort: GC/GEJC Progressed/Non progressed\" for this outcome measure as per planned analysis.","reportingStatus":"POSTED","timeFrame":"At Day 15, 29, 43, 57, 71, 85, 99, 127 and 169","title":"Dose Expansion Phase: Minimum Serum Post-dose (Ctrough) Concentration of Avelumab","type":"SECONDARY","unitOfMeasure":"Microgram per milliliter"}